Galectin Therapeutics | GALT - Pre Tax Profit

Stock Price
2.97
Daily Change
-0.01 -0.17%
Monthly
-4.97%
Yearly
103.08%
Q1 Forecast
2.88

Galectin Therapeutics reported $-12.37M in Pre-Tax Profit for its fiscal quarter ending in June of 2024.





Pre Tax Profit Change Date
AbbVie USD 4.38B 1.92B Sep/2025
Bristol-Myers Squibb USD 3.11B 1.34B Sep/2025
Galectin Therapeutics USD -12.37M 880K Jun/2024
Gilead Sciences USD 3.64B 1.21B Sep/2025
Immunic USD -21.38M 8.2M Jun/2024
Incyte USD 389.94M 92.37M Dec/2025
Merck USD 6.74B 22M Sep/2025